ArchiMed-backed NAMSA, a medical device-focused contract research organization, agreed to acquire American Preclinical Services, a Minneapolis-based full service preclinical CRO. Financial terms were not disclosed. “With NAMSA’s trusted biocompatibility and biological safety solutions, coupled with both organization’s preclinical services, Sponsors now have a clear choice when partnering with the CRO industry’s foremost expert in medical device development and preclinical research,” Michael Conforti, APS President and CEO.